Skip to content
10-K

Annual Report

REGENERX BIOPHARMACEUTICALS, INC.

0001104659-21-030728

← back to feed
Filed
Mar 2, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Feb 25, 2021 133.55M sh
Shares Diluted FY 2020 · Dec 31, 2019 130.97M sh
Operating Cash Flow FY 2020 · Dec 31, 2019 −$1.14M
Cash And Equivalents FY 2020 · Dec 31, 2019 $639.92K
Current Liabilities FY 2020 · Dec 31, 2019 $242.47K
Total Liabilities FY 2020 · Dec 31, 2019 $3.05M
Current Assets FY 2020 · Dec 31, 2019 $681.56K
Total Assets FY 2020 · Dec 31, 2019 $711.76K
Eps Diluted FY 2020 · Dec 31, 2019 −$0.01
Eps Basic FY 2020 · Dec 31, 2019 −$0.01
Sga Expense FY 2020 · Dec 31, 2019 $1.27M
Rd Expense FY 2020 · Dec 31, 2019 $65.11K
Net Income FY 2020 · Dec 31, 2019 −$1.4M
Operating Income FY 2020 · Dec 31, 2019 −$1.26M
Revenue FY 2020 · Dec 31, 2019 $76.76K
Stockholders Equity FY 2020 · Dec 31, 2018 −$2.21M
Cost Of Revenue FY 2020 · Dec 31, 2011 $25K